Rifaximin oral tablet — Competitive Intelligence Brief

Rifaximin oral tablet (Rifaximin oral tablet) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Rifamycin antibiotic. Area: Gastroenterology / Infectious Disease.

marketed Rifamycin antibiotic Bacterial RNA polymerase Gastroenterology / Infectious Disease Small molecule

Target snapshot

Rifaximin oral tablet (Rifaximin oral tablet) — Yokohama City University. Rifaximin is a non-absorbed antibiotic that inhibits bacterial RNA polymerase to reduce pathogenic gut bacteria.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Rifaximin oral tablet TARGET	Rifaximin oral tablet	Yokohama City University	marketed	Rifamycin antibiotic	Bacterial RNA polymerase
clarithromycin, rifabutin	clarithromycin, rifabutin	The University of Texas Health Science Center at Tyler	marketed	Macrolide antibiotic and rifamycin antibiotic combination	Bacterial 50S ribosomal subunit (clarithromycin); bacterial RNA polymerase (rifabutin)
Rifaximin (drug)	Rifaximin (drug)	Państwowy Instytut Medyczny Ministerstwa Spraw Wewnętrznych i Administracji	marketed	Rifamycin antibiotic	Bacterial RNA polymerase
RIF	RIF	South China Children's Leukemia Group	marketed	Rifamycin antibiotic	Bacterial RNA polymerase
HR	HR	Global Alliance for TB Drug Development	marketed	Anti-tuberculosis agent (fixed-dose combination)	Mycobacterial cell wall (isoniazid) and bacterial RNA polymerase (rifampicin)
Rifabutin/rifampin	Rifabutin/rifampin	The University of Texas Health Science Center at Tyler	marketed	Rifamycin antibiotic	Bacterial RNA polymerase β-subunit
Rifampicin (RIF)	Rifampicin (RIF)	National Institute of Allergy and Infectious Diseases (NIAID)	marketed	Rifamycin antibiotic	Bacterial RNA polymerase (RNAP)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Rifamycin antibiotic class)

1. Institute of Tropical Medicine, Belgium · 2 drugs in this class
2. National Institute of Allergy and Infectious Diseases (NIAID) · 2 drugs in this class
3. National Taiwan University Hospital · 2 drugs in this class
4. Bausch Health Americas, Inc. · 2 drugs in this class
5. South China Children's Leukemia Group · 1 drug in this class
6. Suzhou Zelgen Biopharmaceuticals Co.,Ltd · 1 drug in this class
7. TenNor Therapeutics (Suzhou) Limited · 1 drug in this class
8. The University of Texas Health Science Center at Tyler · 1 drug in this class
9. University College, London · 1 drug in this class
10. University of California, San Francisco · 1 drug in this class